Akebia Therapeutics公布的最新数据显示，其药物Vafseo与对照药物Esa在患者死亡率方面未显示出统计学上的显著差异。具体数值上，Vafseo组的死亡率记录为每百患者年8.77%，而Esa组则为8.78%。这一结果突显了两者在关键安全性指标上的高度相似性。
Akebia Therapeutics公布的最新数据显示，其药物Vafseo与对照药物Esa在患者死亡率方面未显示出统计学上的显著差异。具体数值上，Vafseo组的死亡率记录为每百患者年8.77%，而Esa组则为8.78%。这一结果突显了两者在关键安全性指标上的高度相似性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.